Posts

Posted on

Reservoir Media to Release Second Quarter Fiscal Year 2023 Results on November 8, 2022

NEW YORK, Oct. 25, 2022 (GLOBE NEWSWIRE) — Reservoir Media, Inc. (NASDAQ: RSVR) (“Reservoir” or the “Company”), an award-winning independent music company, today announced that it will release financial results for the second fiscal quarter ended September 30, 2022, before market open on Tuesday, November 8, 2022.

Reservoir will host a conference call to discuss its results at 10 a.m. Eastern Standard Time the same day. A live audio webcast of Reservoir’s second fiscal quarter results discussion will be accessible under the Events and Presentations section of the Company’s Investor Relations website at https://investors.reservoir-media.com/news-and-events/events-and-presentations. An archived version of the Company’s webcast will also be available on Reservoir’s website.

Interested parties may also participate in the call using the registration link here. Once registered, participants will receive a dial-in number as well as a PIN to enter the event. Participants may reregister for the conference call in the event of a lost dial-in number or PIN.

To access the call, please log in approximately 10 minutes before the start of the call.

About Reservoir Media, Inc.

Reservoir is an independent music company based in New York City and with offices in Los Angeles, Nashville, Toronto, London, and Abu Dhabi. Reservoir is the first female-founded and led publicly traded independent music company in the U.S. Founded as a family-owned music publisher in 2007, Reservoir has grown to represent over 140,000 copyrights and 36,000 master recordings with titles dating as far back as 1900 and hundreds of #1 releases worldwide. Reservoir frequently holds a Top 10 U.S. Market Share according to Billboard’s Publishers Quarterly, was twice named Publisher of the Year by Music Business Worldwide’s The A&R Awards and won Independent Publisher of the Year at the 2020 and 2022 Music Week Awards.

Reservoir also represents a multitude of recorded music through Chrysalis Records, Tommy Boy Records, and Philly Groove Records and manages artists through its ventures with Blue Raincoat Music and Big Life Management.

Media Contact

Reservoir
Suzy Arrabito
Vice President, Marketing & Communications
[email protected]
www.reservoir-media.com

Investor Contact

Alpha IR Group
Jackie Marcus or Alec Buchmelter
[email protected]

Source: Reservoir Media, Inc.



Posted on

Viant Announces Date of Third Quarter 2022 Financial Results and Conference Call

Viant Announces Date of Third Quarter 2022 Financial Results and Conference Call

IRVINE, Calif.–(BUSINESS WIRE)–Viant Technology Inc. (NASDAQ: DSP), a leading people-based advertising software company, today announced it will release its third quarter 2022 financial results after U.S. markets close on Wednesday, November 9, 2022. Viant will host a conference call and webcast that day at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss the business and financial performance.

Third Quarter 2022 Results and Conference Call

Date:

Wednesday, November 9, 2022

 

 

Time:

2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time

 

 

Webcast:

https://investors.viantinc.com

Approximately one hour after completion of the live call, an archived version of the webcast will be available on the Company’s investor relations website at https://investors.viantinc.com.

About Viant

Viant® (NASDAQ: DSP) is a leading advertising software company that enables marketers to plan, execute and measure omnichannel ad campaigns through a cloud-based platform. Viant’s self-service Demand Side Platform, Adelphic®, powers programmatic advertising across Connected TV, Linear TV, mobile, desktop, audio, gaming and digital out-of-home channels. In 2022, Viant was recognized as a Leader in the DSP category, earned Great Place to Work® certification and Co-Founders Tim and Chris Vanderhook were named EY Entrepreneurs of the Year. To learn more, please visit viantinc.com.

Investor Contact:

Keenan Zopf

[email protected]

Media Contact:

Sondra Magness

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Marketing Data Management Advertising Communications Security Technology Software

MEDIA:

Posted on

Spotify Technology S.A. Releases Financial Results for Third Quarter 2022

Spotify Technology S.A. Releases Financial Results for Third Quarter 2022

NEW YORK–(BUSINESS WIRE)–
Spotify Technology S.A. (NYSE: SPOT) has released its financial results for the third quarter of 2022 by posting an update on its Investor website. Please visit investors.spotify.com to view the update.

As previously announced, the company will host a live question and answer session to discuss third quarter 2022 financial results at 4:30 p.m. Eastern Time. Daniel Ek, our Founder and CEO, and Paul Vogel, our Chief Financial Officer, will be on hand to answer questions submitted through slido.com using the event code #SpotifyEarningsQ322.

What: Spotify Third Quarter 2022 Financial Results Q&A Webcast

When: Tuesday, October 25, 2022

Time: 4:30 p.m. Eastern Time

Q3 2022 Update: https://investors.spotify.com/

Webcast: https://event.on24.com/wcc/r/3969731/682FC847ECD784F831C77F58E7B8DCB0

Slido Event Code: #SpotifyEarningsQ322

A live webcast of the earnings call will be accessible at investors.spotify.com and a recording of the webcast will be available following the session.

About Spotify Technology S.A.

Spotify is the world’s most popular audio streaming subscription service with a community of more than 456 million Monthly Active Users and 195 million Premium Subscribers. With a presence in 183 markets, and more than 80 million tracks including 4.7 million podcast titles, it has transformed the way people access and enjoy music and podcasts.

Investor Relations:

Bryan Goldberg

Lauren Katzen

[email protected]

investors.spotify.com

Public Relations:

Dustee Jenkins

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Entertainment Apps/Applications Technology Mobile Entertainment Music Podcast

MEDIA:

Logo
Logo
Posted on

Arcutis to Report Third Quarter Financial Results

WESTLAKE VILLAGE, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, today announced that it will host a conference call and webcast at 5:00 p.m. ET on Tuesday, November 8, 2022, to report its third quarter financial results.

The schedule for the press release and conference call/webcast is as follows:

  • Q3 2022 Press Release: Tuesday, November 8, 2022, after the close of the U.S. financial markets
  • Q3 2022 Earnings Call: Tuesday, November 8, 2022, at 5:00 p.m. ET

A live webcast of the call and the presentation material will be available on the “Events” section of the Company’s investor website. An archived replay of the webcast will be available on the Arcutis investor website following the conference.

About Arcutis

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis harnesses our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp psoriasis, atopic dermatitis, and seborrheic dermatitis. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, and Twitter.

Forward-Looking Statements

This press release contains “forward-looking” statements. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, and our ability to defend our intellectual property. For a further description of the risks and uncertainties applicable to our business, see the “Risk Factors” section of our Form 10-K filed with U.S. Securities and Exchange Commission (SEC) on February 22, 2022, as amended on March 3, 2022, as well as any subsequent filings with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Contacts:



Media



Amanda Sheldon, Head of Corporate Communications
[email protected]



Investors



Eric McIntyre, Head of Investor Relations
[email protected]



Posted on

Corvus Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Ciforadenant as Potential First Line Treatment for Patients with Renal Cell Cancer

BURLINGAME, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the initiation of a Phase 1b/2 clinical trial evaluating ciforadenant as a potential first line therapy for metastatic renal cell cancer (RCC) in combination with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1). The Phase 1b/2 study is being conducted by the Kidney Cancer Research Consortium (KCRC) and is led by The University of Texas MD Anderson Cancer Center, one of seven partner institutions that make up the KCRC. The study is expected to enroll up to 60 patients at KCRC partner institutions.

“Ciforadenant is one of the most studied adenosine receptor antagonists and we have presented encouraging clinical data in very advanced refractory patients with renal cell cancer, demonstrating its anti-tumor activity as a monotherapy and in combination with anti-PD-L1 therapy,” said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. “In addition, we published preclinical data in Cancer Immunology Research in 2018 that showed that ciforadenant combined with anti-CTLA-4 and anti-PD-1 therapy is highly active, which resulted in complete elimination of tumors, even in the setting of treatment of established tumors. Further laboratory studies have uncovered a novel mechanism of action that we believe may synergize with anti-CTLA-4 therapy. Together we believe this provides strong rationale for this Phase 1b/2 clinical trial in first line renal cell cancer and we are excited to partner with the Kidney Cancer Research Consortium, who is leading the clinical trial. And given this is an open-label study, we hope to have preliminary results relatively early in the trial.”

About the Ciforadenant Phase 1b/2 Trial

The open-label Phase 1b/2 clinical trial is expected to enroll up to 60 patients with newly diagnosed or recurrent stage IV clear cell RCC that have not received any prior systemic therapy. Patients will receive ciforadenant 100 mg oral, twice-daily in combination with ipilimumab (anti-CTLA-4) 1mg/kg given once every three weeks for twelve weeks (4 doses) and nivolumab (anti-PD-1) 3mg/kg given once every three weeks. In the Phase 1b portion of the clinical trial (N=8), the primary endpoints are safety, tolerability and anti-tumor activity. In the Phase 2 portion of the clinical trial, the primary endpoint is the percent of patients that achieve a deep response, defined as complete response or depth of partial response of >50% tumor reduction. Historical data has shown that deep responses correlate with prolonged progression free survival and is seen in approximately 35% of patients receiving ipilimumab and nivolumab. The trial design is based on Corvus’ preclinical research published in 2018 in Cancer Immunology Research, which demonstrated antitumor control and complete elimination of tumors in several animal models using ciforadenant in combination with anti-CTLA4 and anti-PD1.

About the Kidney Cancer Research Consortium

The KCRC is comprised of seven partner institutions at top academic research institutions across the country. The pooled expertise of KCRC members ensures the highest quality of clinical study design, accelerated execution of clinical trials, cost-effective access to multiple research centers, and accurate interpretation and reporting of results. The KCRC was founded in 2018 through the Department of Defense (DoD) Consortium Development Award and was subsequently awarded the DoD Clinical Consortium Award in 2020. For more information, visit www.kidneycancerconsortium.org.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus’ lead product candidate is CPI-818, an investigational, oral, small molecule drug that selectively inhibited ITK in preclinical studies and is in a multicenter Phase 1/1b clinical trial in patients with several types of T-cell lymphomas. The Company’s second clinical program, ciforadenant (CPI-444), is an oral, small molecule inhibitor of the A2A receptor. Its third clinical program, mupadolimab (CPI-006), is a humanized monoclonal antibody directed against CD73 that has exhibited immunomodulatory activity and activation of immune cells in preclinical and clinical studies. For more information, visit www.corvuspharma.com.

About
Ciforadenant

Ciforadenant (CPI-444) is an investigational small molecule, oral, checkpoint inhibitor designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of adenosine in the tumor microenvironment to the A2A receptor. Adenosine, a metabolite of ATP (adenosine triphosphate), is produced within the tumor microenvironment where it may bind to the adenosine A2A receptor present on immune cells and block their activity.

Forward-Looking Statements

This press release contains forward-looking statements, including statements related to the potential safety and efficacy of CPI-818, mupadolimab and ciforadenant; the Company’s ability, as well as the timing thereof, to develop and advance product candidates into and successfully complete preclinical studies and clinical trials, including the Company’s Phase 1b/2 clinical trial with ciforadenant in collaboration with the KCRC; the timing of the availability and announcement of clinical data and certain other product development milestones, including the timing of initial results in the Phase 1b/2 clinical trial for ciforadenant; and the expected trial design and number of patients enrolled in the Company’s upcoming planned clinical trials such as the Phase 1b/2 clinical trial for ciforadenant. All statements other than statements of historical fact contained in this press release are forward-looking statements. These statements often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may” or similar expressions. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, filed with the Securities and Exchange Commission on August 8, 2022, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the Company’s ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials of CPI-818, ciforadenant and mupadolimab; the accuracy of the Company’s estimates relating to its ability to initiate and/or complete preclinical studies and clinical trials; the results of preclinical studies may not be predictive of future results; the unpredictability of the regulatory process; regulatory developments in the United States, and other foreign countries; regulatory developments in the United States, and other foreign countries; the costs of clinical trials may exceed expectations; the ability of third-parties to successfully conduct the Company’s clinical trials in a timely manner; and the Company’s ability to raise additional capital. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and the timing of events and circumstances and actual results could differ materially from those projected in the forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

INVESTOR CONTACT:

Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
[email protected]

MEDIA CONTACT:

Aulani Capuchin
Real Chemistry
+1-559-355-2673
[email protected]



Posted on

Boyd Gaming Reports Third-Quarter 2022 Results

Boyd Gaming Reports Third-Quarter 2022 Results

LAS VEGAS–(BUSINESS WIRE)–
Boyd Gaming Corporation (NYSE: BYD) today reported financial results for the third quarter ended September 30, 2022.

Keith Smith, President and Chief Executive Officer of Boyd Gaming, said: “This quarter was another solid performance by our Company, as we achieved third-quarter EBITDAR that was second only to last year’s record quarterly performance. These results were driven by our continued focus on core customers and sustained efficiencies throughout our business, as our operating model is successfully meeting today’s challenges and delivering consistent results. Our strong operating performance is producing robust free cash flow, allowing us to return nearly $500 million in capital to our shareholders so far this year. Overall, we are encouraged by the resiliency of our business, and remain confident in our strategy and our ability to deliver consistent results in the current economic environment.”

Boyd Gaming reported third-quarter 2022 revenues of $877.3 million, increasing from $843.1 million in the third quarter of 2021. The Company reported net income of $157.0 million, or $1.46 per share, for the third quarter of 2022, compared to $138.2 million, or $1.21 per share, for the year-ago period.

Total Adjusted EBITDAR(1) was $337.7 million in the third quarter of 2022, compared to $340.7 million in the third quarter of 2021. Adjusted Earnings(1) for the third quarter of 2022 were $159.2 million, or $1.48 per share, compared to $149.0 million, or $1.30 per share, for the same period in 2021.

(1)

  

See footnotes at the end of the release for additional information relative to non-GAAP financial measures.

Operations Review

In the Las Vegas Locals segment, revenue trends remained consistent with recent quarters as play from core customers continued to grow. EBITDAR for the segment remained well above pre-pandemic levels, rising nearly 75% over the third quarter of 2019 and trailing only last year’s record third quarter. Midwest & South segment results include management fees from Sky River Casino, which opened in August 2022, and contributions from the Company’s online sports-betting partnerships. Excluding these items, on a property-level basis the Midwest & South segment grew revenues slightly year-over-year while EBITDAR nearly matched last year’s record third-quarter results. When compared to the third quarter of 2019, property-level EBITDAR grew 37% in the Midwest & South segment. The Downtown Las Vegas segment delivered record third-quarter EBITDAR and margins, with EBITDAR increasing 49% over the third quarter of 2019. Segment results benefited from strong performance from the Company’s Hawaiian customers, as well as the reopening of Main Street Station in September 2021.

Additional Company Updates

Boyd Gaming opened Sky River Casino near Sacramento, California on August 15, 2022. The Company has a seven-year management agreement to operate Sky River on behalf of the Wilton Rancheria Tribe. Management fees from Sky River are reported within the Company’s Midwest & South segment.

The Company continues to make progress toward completing its previously announced acquisition of Pala Interactive for cash consideration of $170 million, and anticipates it will close the acquisition in the next several weeks.

Dividend and Share Repurchase Program Update

Boyd Gaming paid a quarterly cash dividend of $0.15 per share on October 15, 2022, to shareholders of record on September 30, 2022.

As part of its recurring share repurchase program, the Company repurchased approximately $135 million in stock during the third quarter of 2022. As of September 30, 2022, the Company had approximately $346 million remaining under current share repurchase authorizations.

Balance Sheet Statistics

As of September 30, 2022, Boyd Gaming had cash on hand of $252.3 million, and total debt of $2.91 billion.

Conference Call Information

Boyd Gaming will host a conference call to discuss its third-quarter 2022 results today, October 25, at 5:00 p.m. Eastern. The conference call number is (844) 200-6205, or (833) 950-0062 for Canadian callers and +1 (929) 526-1599 for international callers. The conference call passcode is 589824. Please join up to 15 minutes in advance to ensure you are connected prior to the start of the call.

The conference call will also be available live on the Internet at https://investors.boydgaming.com, or https://events.q4inc.com/attendee/562935205.

A replay will be available by dialing (866) 813-9403 (Canada (226) 828-7578, international +44 204 525 0658) on Tuesday, October 25 after the conclusion of the call, and continuing through Tuesday, November 1. The conference number for the replay is968187. The replay will also be available at https://investors.boydgaming.com.

BOYD GAMING CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

September 30,

 

September 30,
(In thousands, except per share data)

2022

 

2021

 

2022

 

2021
Revenues
Gaming

$

667,975

 

$

674,227

 

$

2,020,854

 

$

2,019,615

 

Food & beverage

 

67,792

 

 

61,101

 

 

201,834

 

 

162,641

 

Room

 

46,672

 

 

44,317

 

 

138,985

 

 

109,384

 

Other

 

94,824

 

 

63,415

 

 

270,783

 

 

198,329

 

Total revenues

 

877,263

 

 

843,060

 

 

2,632,456

 

 

2,489,969

 

Operating costs and expenses
Gaming

 

251,814

 

 

249,685

 

 

756,356

 

 

741,176

 

Food & beverage

 

58,502

 

 

50,659

 

 

169,892

 

 

136,391

 

Room

 

17,783

 

 

15,074

 

 

51,058

 

 

41,413

 

Other

 

57,197

 

 

41,644

 

 

174,699

 

 

128,038

 

Selling, general and administrative

 

92,950

 

 

91,159

 

 

280,659

 

 

271,639

 

Master lease rent expense (a)

 

26,828

 

 

26,306

 

 

79,788

 

 

78,396

 

Maintenance and utilities

 

40,789

 

 

35,868

 

 

108,196

 

 

95,256

 

Depreciation and amortization

 

64,956

 

 

67,586

 

 

194,191

 

 

199,332

 

Corporate expense

 

26,375

 

 

28,264

 

 

90,251

 

 

86,295

 

Project development, preopening and writedowns

 

9,645

 

 

10,646

 

 

528

 

 

13,515

 

Impairment of assets

 

5,575

 

 

—

 

 

5,575

 

 

—

 

Other operating items, net

 

(12,610

)

 

3,023

 

 

(12,324

)

 

15,295

 

Total operating costs and expenses

 

639,804

 

 

619,914

 

 

1,898,869

 

 

1,806,746

 

Operating income

 

237,459

 

 

223,146

 

 

733,587

 

 

683,223

 

Other expense (income)
Interest income

 

(2,073

)

 

(442

)

 

(2,976

)

 

(1,406

)

Interest expense, net of amounts capitalized

 

36,001

 

 

45,171

 

 

110,125

 

 

158,192

 

Loss on early extinguishments and modifications of debt

 

—

 

 

42

 

 

19,809

 

 

65,517

 

Other, net

 

170

 

 

119

 

 

3,667

 

 

2,288

 

Total other expense, net

 

34,098

 

 

44,890

 

 

130,625

 

 

224,591

 

Income before income taxes

 

203,361

 

 

178,256

 

 

602,962

 

 

458,632

 

Income tax provision

 

(46,359

)

 

(40,082

)

 

(136,269

)

 

(104,568

)

Net income

$

157,002

 

$

138,174

 

$

466,693

 

$

354,064

 

 
Basic net income per common share

$

1.46

 

$

1.21

 

$

4.24

 

$

3.11

 

Weighted average basic shares outstanding

 

107,743

 

 

114,095

 

 

110,002

 

 

113,835

 

 
Diluted net income per common share

$

1.46

 

$

1.21

 

$

4.24

 

$

3.10

 

Weighted average diluted shares outstanding

 

107,840

 

 

114,284

 

 

110,135

 

 

114,099

 

____________________
(a) Rent expense incurred by those properties subject to a master lease with a real estate investment trust.

BOYD GAMING CORPORATION

SUPPLEMENTAL INFORMATION

Reconciliation of Adjusted EBITDA to Net Income

(Unaudited)

 

 

 

 

 

 

Three Months Ended

Nine Months Ended

 

September 30,

September 30,
(In thousands)

2022

2021

2022

2021
Total Revenues by Reportable Segment
Las Vegas Locals

$

225,791

 

$

231,264

 

$

689,814

 

$

649,782

 

Downtown Las Vegas

 

49,507

 

 

42,137

 

 

152,890

 

 

102,350

 

Midwest & South

 

601,965

 

 

569,659

 

 

1,789,752

 

 

1,737,837

 

Total revenues

$

877,263

 

$

843,060

 

$

2,632,456

 

$

2,489,969

 

 
Adjusted EBITDAR by Reportable Segment
Las Vegas Locals

$

111,733

 

$

125,360

 

$

355,762

 

$

349,572

 

Downtown Las Vegas

 

17,704

 

 

13,222

 

 

58,216

 

 

31,083

 

Midwest & South

 

230,195

 

 

222,058

 

 

682,725

 

 

700,199

 

Property Adjusted EBITDAR

 

359,632

 

 

360,640

 

 

1,096,703

 

 

1,080,854

 

Corporate expense, net of share-based compensation expense (a)

 

(21,934

)

 

(19,943

)

 

(66,296

)

 

(62,165

)

Adjusted EBITDAR

 

337,698

 

 

340,697

 

 

1,030,407

 

 

1,018,689

 

Master lease rent expense (b)

 

(26,828

)

 

(26,306

)

 

(79,788

)

 

(78,396

)

Adjusted EBITDA

 

310,870

 

 

314,391

 

 

950,619

 

 

940,293

 

 
Other operating costs and expenses
Deferred rent

 

192

 

 

207

 

 

576

 

 

621

 

Depreciation and amortization

 

64,956

 

 

67,586

 

 

194,191

 

 

199,332

 

Share-based compensation expense

 

5,653

 

 

9,783

 

 

28,486

 

 

28,307

 

Project development, preopening and writedowns

 

9,645

 

 

10,646

 

 

528

 

 

13,515

 

Impairment of assets

 

5,575

 

 

—

 

 

5,575

 

 

—

 

Other operating items, net

 

(12,610

)

 

3,023

 

 

(12,324

)

 

15,295

 

Total other operating costs and expenses

 

73,411

 

 

91,245

 

 

217,032

 

 

257,070

 

Operating income

 

237,459

 

 

223,146

 

 

733,587

 

 

683,223

 

Other expense (income)
Interest income

 

(2,073

)

 

(442

)

 

(2,976

)

 

(1,406

)

Interest expense, net of amounts capitalized

 

36,001

 

 

45,171

 

 

110,125

 

 

158,192

 

Loss on early extinguishments and modifications of debt

 

—

 

 

42

 

 

19,809

 

 

65,517

 

Other, net

 

170

 

 

119

 

 

3,667

 

 

2,288

 

Total other expense, net

 

34,098

 

 

44,890

 

 

130,625

 

 

224,591

 

Income before income taxes

 

203,361

 

 

178,256

 

 

602,962

 

 

458,632

 

Income tax provision

 

(46,359

)

 

(40,082

)

 

(136,269

)

 

(104,568

)

Net income

$

157,002

 

$

138,174

 

$

466,693

 

$

354,064

 

____________________
(a) Reconciliation of corporate expense:
 

Three Months Ended

 

Nine Months Ended

September 30,

 

September 30,
(In thousands)

2022

 

2021

 

2022

 

2021
Corporate expense as reported on Condensed Consolidated Statements of Operations

$

26,375

 

$

28,264

 

$

90,251

 

$

86,295

 

Corporate share-based compensation expense

 

(4,441

)

 

(8,321

)

 

(23,955

)

 

(24,130

)

Corporate expense, net, as reported on the above table

$

21,934

 

$

19,943

 

$

66,296

 

$

62,165

 

 
(b) Rent expense incurred by those properties subject to a master lease with a real estate investment trust.
 

BOYD GAMING CORPORATION

SUPPLEMENTAL INFORMATION

Reconciliations of Net Income to Adjusted Earnings

and Net Income Per Share to Adjusted Earnings Per Share

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

September 30,

 

September 30,
(In thousands, except per share data)

2022

 

2021

 

2022

 

2021
Net income

$

157,002

 

$

138,174

 

$

466,693

 

$

354,064

 

Pretax adjustments:
Project development, preopening and writedowns

 

9,645

 

 

10,646

 

 

528

 

 

13,515

 

Impairment of assets

 

5,575

 

 

—

 

 

5,575

 

 

—

 

Other operating items, net

 

(12,610

)

 

3,023

 

 

(12,324

)

 

15,295

 

Loss on early extinguishments and modifications of debt

 

—

 

 

42

 

 

19,809

 

 

65,517

 

Other, net

 

170

 

 

119

 

 

3,667

 

 

2,288

 

Total adjustments

 

2,780

 

 

13,830

 

 

17,255

 

 

96,615

 

 
Income tax effect for above adjustments

 

(616

)

 

(2,992

)

 

(3,712

)

 

(20,843

)

Adjusted earnings

$

159,166

 

$

149,012

 

$

480,236

 

$

429,836

 

 
Net income per share, diluted

$

1.46

 

$

1.21

 

$

4.24

 

$

3.10

 

Pretax adjustments:
Project development, preopening and writedowns

 

0.09

 

 

0.09

 

 

—

 

 

0.12

 

Impairment of assets

 

0.05

 

 

—

 

 

0.05

 

 

—

 

Other operating items, net

 

(0.11

)

 

0.03

 

 

(0.11

)

 

0.13

 

Loss on early extinguishments and modifications of debt

 

—

 

 

—

 

 

0.18

 

 

0.58

 

Other, net

 

—

 

 

—

 

 

0.03

 

 

0.02

 

Total adjustments

 

0.03

 

 

0.12

 

 

0.15

 

 

0.85

 

 
Income tax effect for above adjustments

 

(0.01

)

 

(0.03

)

 

(0.03

)

 

(0.18

)

Adjusted earnings per share, diluted

$

1.48

 

$

1.30

 

$

4.36

 

$

3.77

 

 
Weighted average diluted shares outstanding

 

107,840

 

 

114,284

 

 

110,135

 

 

114,099

 

Non-GAAP Financial Measures

Our financial presentations include the following non-GAAP financial measures:

  • EBITDA: earnings before interest, taxes, depreciation and amortization,
  • Adjusted EBITDA: EBITDA adjusted for deferred rent, share-based compensation expense, project development, preopening and writedown expenses, impairments of assets, other operating items, net, gain or loss on early extinguishments and modifications of debt and other items, net,
  • EBITDAR: EBITDA further adjusted for rent expense associated with master leases with a real estate investment trust,
  • Adjusted EBITDAR: Adjusted EBITDA further adjusted for rent expense associated with master leases with a real estate investment trust,
  • Adjusted Earnings: net income before project development, preopening and writedown expenses, impairments of assets, other operating items, net, gain or loss on early extinguishments and modifications of debt, and other non-recurring adjustments, net, and,
  • Adjusted Earnings Per Share (Adjusted EPS): Adjusted Earnings divided by weighted average diluted shares outstanding.

Collectively, we refer to these and other non-GAAP financial measures as the “Non-GAAP Measures”.

The Non-GAAP Measures are commonly used measures of performance in our industry that we believe, when considered with measures calculated in accordance with accounting principles generally accepted in the United States (GAAP), provide our investors with a more complete understanding of our operating results and facilitates comparisons between us and our competitors. We provide this information to investors to enable them to perform comparisons of our past, present and future operating results and as a means to evaluate the results of core on-going operations. We have historically reported these measures to our investors and believe that the continued inclusion of the Non-GAAP Measures provides consistency in our financial reporting. We also believe this information is useful to investors in allowing greater transparency related to significant measures used by our management in their financial and operational decision-making, their evaluation of total company and individual property performance, in the evaluation of incentive compensation and in the annual budget process. Management also uses Non-GAAP Measures in the evaluation of potential acquisitions and dispositions. We believe these measures continue to be used by investors in their assessment of our operating performance and the valuation of our company.

The use of Non-GAAP Measures has certain limitations. Our presentation of the Non-GAAP Measures may be different from the presentation used by other companies and therefore comparability may be limited. While excluded from certain of the Non-GAAP Measures, depreciation and amortization expense, interest expense, income taxes and other items have been and will be incurred. Each of these items should also be considered in the overall evaluation of our results. Additionally, the Non-GAAP Measures do not consider capital expenditures and other investing activities and should not be considered as a measure of our liquidity. We compensate for these limitations by providing the relevant disclosure of our depreciation and amortization, interest and income taxes, capital expenditures and other items both in our reconciliations to the historical GAAP financial measures and in our consolidated financial statements, all of which should be considered when evaluating our performance. We do not provide a reconciliation of forward-looking Non-GAAP Measures to the corresponding forward-looking GAAP measure due to our inability to project special charges and certain expenses.

The Non-GAAP Measures are to be used in addition to and in conjunction with results presented in accordance with GAAP. The Non-GAAP Measures should not be considered as an alternative to net income, operating income, or any other operating performance measure prescribed by GAAP, nor should these measures be relied upon to the exclusion of GAAP financial measures. The Non-GAAP Measures reflect additional ways of viewing our operations that we believe, when viewed with our GAAP results and the reconciliations to the corresponding historical GAAP financial measures, provide a more complete understanding of factors and trends affecting our business than could be obtained absent this disclosure. Management strongly encourages investors to review our financial information in its entirety and not to rely on a single financial measure.

Forward-looking Statements and Company Information

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as “may,” “will,” “might,” “expect,” “believe,” “anticipate,” “could,” “would,” “estimate,” “continue,” “pursue,” or the negative thereof or comparable terminology, and may include (without limitation) information regarding the Company’s expectations, goals or intentions regarding future performance. In addition, forward-looking statements in this press release, as well as in our earnings conference call remarks, include statements regarding continued growth in visitation and spending among the Company’s core customers, the Company’s views that it will be able to drive continued revenue and EBITDAR growth throughout its business, the impacts of COVID-19 on the Company, the Company’s operating strategy, the Company’s confidence in its long-term growth trajectory, and the Company’s plans with respect to share repurchases and returning capital to shareholders. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These risks and uncertainties include but are not limited to: the ongoing uncertainty about COVID-19, its duration and impact, the extent of consumer demand, potential negative effects on the Company’s workforce, suppliers, contractors and other partners, as well as the impact on the customer experience of necessary health and safety measures implemented at the direction of state and local governments and gaming regulators. Risks also include fluctuations in the Company’s operating results; the political climate and its effects on consumer spending and its impact on the travel industry; the state of the economy and its effect on consumer spending; the impact and effects of the local economies in the markets where the Company operates; the receipt of legislative, and other state, federal and local approvals for the Company’s development projects; developments in legalization of online gaming, the Company’s ability to operate online gaming profitably, or otherwise; consumer reaction to fluctuations in the stock market and economic factors; the effects of events adversely impacting the economy or the regions from which the Company draws a significant percentage of its customers; competition; litigation; financial community and rating agency perceptions of the Company; changes in laws and regulations, weather, regulation, economic, credit and capital market conditions; and the effects of war, terrorist or similar activity. Additional factors that could cause actual results to differ are discussed under the heading “Risk Factors” and in other sections of the Company’s Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and in the Company’s other current and periodic reports filed from time to time with the SEC. All forward-looking statements in this press release are made as of the date hereof, based on information available to the Company as of the date hereof, and the Company assumes no obligation to update any forward-looking statement.

About Boyd Gaming

Founded in 1975, Boyd Gaming Corporation (NYSE: BYD) is a leading geographically diversified operator of 28 gaming entertainment properties in 10 states, and manager of a tribal casino in northern California. The Company is also a strategic partner and 5% equity owner of FanDuel Group, the nation’s leading sports-betting operator. With one of the most experienced leadership teams in the casino industry, Boyd Gaming prides itself on offering its guests an outstanding entertainment experience, delivered with unwavering attention to customer service. Through a long-standing company philosophy called Caring the Boyd Way, Boyd Gaming is committed to advancing Environmental, Social and Corporate Governance (ESG) initiatives that positively impact the Company’s stakeholders and communities. For additional Company information and press releases, visit https://investors.boydgaming.com.

Financial Contact:

Josh Hirsberg

(702) 792-7234

[email protected]

Media Contact:

David Strow

(702) 792-7386

[email protected]

KEYWORDS: United States North America Nevada

INDUSTRY KEYWORDS: Lodging Destinations Travel Electronic Games Online Casino/Gaming Mobile Entertainment Entertainment Retail Restaurant/Bar Other Travel

MEDIA:

Logo
Logo
Posted on

First Trust Advisors L.P. Announces Portfolio Manager Update for First Trust Mortgage Income Fund

First Trust Advisors L.P. Announces Portfolio Manager Update for First Trust Mortgage Income Fund

WHEATON, Ill.–(BUSINESS WIRE)–
First Trust Advisors L.P. (“FTA”) announced today that First Trust Advisors L.P. (“First”), investment sub-advisor for FMY (NYSE: FMY) (the “Fund”), will release an update on the market and the Fund for financial professionals and investors. To listen to the update, click on the following link:

FMY Replay 10/27/2022

The update will be available from Thursday, October 27, 2022, at 5:00 P.M. Eastern Time until 5:00 P.M. Eastern Time on Saturday, November 26, 2022.

FTA is a federally registered investment advisor and serves as the Fund’s investment advisor. FTA and its affiliate First Trust Portfolios L.P. (“FTP”), a FINRA registered broker-dealer, are privately-held companies that provide a variety of investment services. FTA has collective assets under management or supervision of approximately $178 billion as of September 30, 2022 through unit investment trusts, exchange-traded funds, closed-end funds, mutual funds and separate managed accounts. FTA is the supervisor of the First Trust unit investment trusts, while FTP is the sponsor. FTP is also a distributor of mutual fund shares and exchange-traded fund creation units. FTA and FTP are based in Wheaton, Illinois.

Principal Risk Factors: Risks are inherent in all investing. Certain risks applicable to the Fund are identified below, which includes the risk that you could lose some or all of your investment in the Fund. The principal risks of investing in the Fund are spelled out in the Fund’s annual shareholder reports. The order of the below risk factors does not indicate the significance of any particular risk factor. The Fund also files reports, proxy statements and other information that is available for review.

Past performance is no assurance of future results. Investment return and market value of an investment in the Fund will fluctuate. Shares, when sold, may be worth more or less than their original cost. There can be no assurance that the Fund’s investment objectives will be achieved. The Fund may not be appropriate for all investors.

Securities held by a fund, as well as shares of a fund itself, are subject to market fluctuations caused by factors such as general economic conditions, political events, regulatory or market developments, changes in interest rates and perceived trends in securities prices. Shares of a fund could decline in value or underperform other investments as a result of the risk of loss associated with these market fluctuations. In addition, local, regional or global events such as war, acts of terrorism, spread of infectious diseases or other public health issues, recessions, or other events could have a significant negative impact on a fund and its investments. Such events may affect certain geographic regions, countries, sectors and industries more significantly than others. In February 2022, Russia invaded Ukraine which has caused and could continue to cause significant market disruptions and volatility within the markets in Russia, Europe, and the United States. The hostilities and sanctions resulting from those hostilities could have a significant impact on certain fund investments as well as fund performance. The COVID-19 global pandemic and the ensuing policies enacted by governments and central banks have caused and may continue to cause significant volatility and uncertainty in global financial markets. While the U.S. has resumed “reasonably” normal business activity, many countries continue to impose lockdown measures. Additionally, there is no guarantee that vaccines will be effective against emerging variants of the disease.

The debt securities in which the Fund invests are subject to certain risks, including issuer risk, reinvestment risk, prepayment risk, credit risk, interest rate risk and liquidity risk.. Issuer risk is the risk that the value of fixed-income securities may decline for a number of reasons which directly relate to the issuer. Reinvestment risk is the risk that income from the Fund’s portfolio will decline if the Fund invests the proceeds from matured, traded or called bonds at market interest rates that are below the Fund portfolio’s current earnings rate. Prepayment risk is the risk that, upon a prepayment, the actual outstanding debt on which the Fund derives interest income will be reduced. Credit risk is the risk that an issuer of a security will be unable or unwilling to make dividend, interest and/or principal payments when due and that the value of a security may decline as a result. Interest rate risk is the risk that fixed-income securities will decline in value because of changes in market interest rates. Liquidity risk is the risk that illiquid and restricted securities may be difficult to value and to dispose of at a fair price at the times when the Fund believes it is desirable to do so.

A mortgage-backed security may be negatively affected by the quality of the mortgages underlying such security and the structure of its issuer. For example, if a mortgage underlying a particular mortgage-backed security defaults, the value of that security may decrease. Moreover, a downturn in the markets for residential or commercial real estate or a general economic downturn could negatively affect both the price and liquidity of privately issued mortgage-backed securities. A portion of the Fund’s managed assets may be invested in subordinated classes of mortgage-backed securities. Such subordinated classes are subject to a greater degree of non-payment risk than are senior classes of the same issuer or agency.

To the extent a fund invests in floating or variable rate obligations that use the London Interbank Offered Rate (“LIBOR”) as a reference interest rate, it is subject to LIBOR Risk. The United Kingdom’s Financial Conduct Authority, which regulates LIBOR has ceased making LIBOR available as a reference rate over a phase-out period that began December 31, 2021. There is no assurance that any alternative reference rate, including the Secured Overnight Financing Rate (“SOFR”) will be similar to or produce the same value or economic equivalence as LIBOR or that instruments using an alternative rate will have the same volume or liquidity. The unavailability or replacement of LIBOR may affect the value, liquidity or return on certain fund investments and may result in costs incurred in connection with closing out positions and entering into new trades. Any potential effects of the transition away from LIBOR on the fund or on certain instruments in which the fund invests can be difficult to ascertain, and they may vary depending on a variety of factors, and they could result in losses to the fund.

Investments in asset-backed or mortgage-backed securities offered by non-governmental issuers, such as commercial banks, savings and loans, private mortgage insurance companies, mortgage bankers and other secondary market issuers are subject to additional risks.

The primary risks associated with the use of futures contracts are (a) the imperfect correlation between the change in market value of the instruments or indices underlying the futures contracts and the price of the futures contracts; (b) possible lack of a liquid secondary market for a futures contract and the resulting inability to close a futures contract when desired; (c) losses caused by unanticipated market movements, which are potentially unlimited; (d) the investment adviser’s inability to predict correctly the direction of securities prices, interest rates, currency exchange rates and other economic factors; and (e) the possibility that the counterparty will default in the performance of its obligations.

If a security sold short increases in price, the Fund may have to cover its short position at a higher price than the short sale price, resulting in a loss.

Repurchase agreements are subject to the risk of failure. If the Fund’s counterparty defaults on its obligations and the Fund is delayed or prevented from recovering the collateral, or if the value of the collateral is insufficient, the Fund may realize a loss.

Use of leverage can result in additional risk and cost, and can magnify the effect of any losses.

The risks of investing in the Fund are spelled out in the shareholder reports and other regulatory filings.

The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.

The Fund’s daily closing New York Stock Exchange price and net asset value per share as well as other information can be found at www.ftportfolios.com or by calling 1-800-988-5891.

 

JEFF MARGOLIN — (630) 915-6784

KEYWORDS: Illinois United States North America

INDUSTRY KEYWORDS: Professional Services Finance

MEDIA:

Logo
Logo
Posted on

Intevac to Announce Third Quarter Results on November 2nd

Intevac to Announce Third Quarter Results on November 2nd

SANTA CLARA, Calif.–(BUSINESS WIRE)–
Intevac, Inc. (Nasdaq: IVAC), a leading supplier of thin-film processing systems, will release financial results for its fiscal third quarter 2022 at approximately 1 p.m. PT (4 p.m. ET) on Wednesday, November 2nd, 2022.

At 1:30 p.m. PT (4:30 p.m. ET) on November 2nd, Intevac management will host a teleconference to discuss the Company’s financial results.

To participate in the teleconference, please call toll-free (877) 407-0989 prior to the start time, and reference meeting number 13733249. For international callers, the dial-in number is +1 (201) 389-0921. You may also listen live via the Internet at https://www.webcast-eqs.com/intevac_q32022_en/en or on the Company’s investor relations website at https://ir.intevac.com/. For those unable to attend live, an archived webcast of the call will be available at the same link.

About Intevac

Founded in 1991, we are the world’s leading provider of hard disk drive (HDD) media processing systems. Over the last 20 years, we have delivered over 180 200 Lean® systems, which currently represent at least 65% of the world’s capacity for HDD disk media production. Today, we believe that all of the new media capacity additions for the HDD industry are being deployed on our 200 Lean platform. With over 30 years of leadership in designing, developing, and manufacturing high-productivity, thin-film processing systems, we also have opportunities to leverage our technology in additional applications, such as protective coatings for the display cover glass market. For more information call 408-986-9888, or visit the Company’s website at www.intevac.com.

James Moniz

Chief Financial Officer

(408) 986-9888

Claire McAdams

Investor Relations

(530) 265-9899

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Technology Hardware Other Technology Data Management

MEDIA:

Posted on

Masimo to Report Third Quarter 2022 Financial Results after Market Close on Tuesday, November 8

Masimo to Report Third Quarter 2022 Financial Results after Market Close on Tuesday, November 8

Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET)

IRVINE, Calif.–(BUSINESS WIRE)–
Masimo (NASDAQ: MASI) will release third quarter 2022 financial results for the period ended October 1, 2022, after the market closes on Tuesday, November 8, 2022. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Joe Kiani, Chairman and Chief Executive Officer, and Micah Young, Executive Vice President and Chief Financial Officer.

To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with details including the dial-in number and a registrant ID number. Reminders about the call will also be sent to registered participants via email.

Conference Call Registration Link (Please register to obtain the dial-in number):

https://conferencingportals.com/event/nUSpRIEm

A replay of the webcast and conference call will be available shortly after the conclusion of the call and will be archived on the Company’s website.

About Masimo

Masimo (Nasdaq: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve patient outcomes and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies. Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates, improve CCHD screening in newborns, and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs. Masimo SET® is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world, and is the primary pulse oximetry at 9 of the top 10 hospitals listed in the 2018-19 U.S. News and World Report Best Hospitals Honor Roll. Masimo continues to refine SET® and in 2018, announced that SpO2 accuracy on RD SET™ sensors during conditions of motion has been significantly improved, providing clinicians with even greater confidence that the SpO2 values they rely on accurately reflect a patient’s physiological status. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography with NomoLine® sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7® and Radius PPG™, portable devices like Rad-67™, fingertip pulse oximeters like MightySat® Rx, and devices available for use both in the hospital and at home, such as Rad-97™. Masimo hospital automation and connectivity solutions are centered around the Iris® platform, and include Iris Gateway™, Patient SafetyNet, Replica™, Halo ION™, UniView™, and Doctella™. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at www.masimo.com/evidence/featured-studies/feature/.

ORi and RPVi have not received FDA 510(k) clearance and are not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI are trademarks or registered trademarks of Masimo.

Investor Contact: Eli Kammerman

(949) 297-7077

[email protected]

Media Contact: Evan Lamb

(949) 297-3376

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Biotechnology General Health Health Medical Devices

MEDIA:

Posted on

Custom Truck One Source to Announce Third Quarter 2022 Financial Results

Custom Truck One Source to Announce Third Quarter 2022 Financial Results

KANSAS CITY, Mo.–(BUSINESS WIRE)–
Custom Truck One Source, Inc. (“Custom Truck One Source” or the “Company”) (NYSE: CTOS) today announced it will release third quarter 2022 financial results after the market close on Tuesday, November 8, 2022.

Management will discuss the results on a conference call at 5:00 p.m. ET on Tuesday, November 8, 2022. The webcast and a presentation of financial information will be publicly available at investors.customtruck.com. To listen by phone, please dial 1-877-425-9470 or 1-201-389-0878. A replay of the call will be available until midnight ET, Tuesday, November 15, 2022, by dialing 1-844-512-2921 or 1-412-317-6671 and entering passcode 13733083.

ABOUT CUSTOM ONE TRUCK ONE SOURCE

Custom Truck One Source is a leading provider of specialized truck and heavy equipment solutions to the utility, telecommunications, rail and infrastructure markets in North America. The Company’s solutions include rentals, sales, aftermarket parts, tools, accessories and service, equipment production, manufacturing, financing solutions, and asset disposal. With vast equipment breadth, the Company’s team of experts service its customers across an integrated network of locations across North America. For more information, please visit customtruck.com.

INVESTOR CONTACT

Brian Perman, Vice President, Investor Relations

844-403-6138

[email protected]

KEYWORDS: United States North America Missouri

INDUSTRY KEYWORDS: Automotive Manufacturing Manufacturing General Automotive Automotive Performance & Special Interest

MEDIA:

Logo
Logo